Cargando…
Two-Year Event-Free Survival Prediction in DLBCL Patients Based on In Vivo Radiomics and Clinical Parameters
PURPOSE: For the identification of high-risk patients in diffuse large B-cell lymphoma (DLBCL), we investigated the prognostic significance of in vivo radiomics derived from baseline [(18)F]FDG PET/CT and clinical parameters. METHODS: Pre-treatment [(18)F]FDG PET/CT scans of 85 patients diagnosed wi...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216187/ https://www.ncbi.nlm.nih.gov/pubmed/35756658 http://dx.doi.org/10.3389/fonc.2022.820136 |
_version_ | 1784731374061617152 |
---|---|
author | Ritter, Zsombor Papp, László Zámbó, Katalin Tóth, Zoltán Dezső, Dániel Veres, Dániel Sándor Máthé, Domokos Budán, Ferenc Karádi, Éva Balikó, Anett Pajor, László Szomor, Árpád Schmidt, Erzsébet Alizadeh, Hussain |
author_facet | Ritter, Zsombor Papp, László Zámbó, Katalin Tóth, Zoltán Dezső, Dániel Veres, Dániel Sándor Máthé, Domokos Budán, Ferenc Karádi, Éva Balikó, Anett Pajor, László Szomor, Árpád Schmidt, Erzsébet Alizadeh, Hussain |
author_sort | Ritter, Zsombor |
collection | PubMed |
description | PURPOSE: For the identification of high-risk patients in diffuse large B-cell lymphoma (DLBCL), we investigated the prognostic significance of in vivo radiomics derived from baseline [(18)F]FDG PET/CT and clinical parameters. METHODS: Pre-treatment [(18)F]FDG PET/CT scans of 85 patients diagnosed with DLBCL were assessed. The scans were carried out in two clinical centers. Two-year event-free survival (EFS) was defined. After delineation of lymphoma lesions, conventional PET parameters and in vivo radiomics were extracted. For 2-year EFS prognosis assessment, the Center 1 dataset was utilized as the training set and underwent automated machine learning analysis. The dataset of Center 2 was utilized as an independent test set to validate the established predictive model built by the dataset of Center 1. RESULTS: The automated machine learning analysis of the Center 1 dataset revealed that the most important features for building 2-year EFS are as follows: max diameter, neighbor gray tone difference matrix (NGTDM) busyness, total lesion glycolysis, total metabolic tumor volume, and NGTDM coarseness. The predictive model built on the Center 1 dataset yielded 79% sensitivity, 83% specificity, 69% positive predictive value, 89% negative predictive value, and 0.85 AUC by evaluating the Center 2 dataset. CONCLUSION: Based on our dual-center retrospective analysis, predicting 2-year EFS built on imaging features is feasible by utilizing high-performance automated machine learning. |
format | Online Article Text |
id | pubmed-9216187 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92161872022-06-23 Two-Year Event-Free Survival Prediction in DLBCL Patients Based on In Vivo Radiomics and Clinical Parameters Ritter, Zsombor Papp, László Zámbó, Katalin Tóth, Zoltán Dezső, Dániel Veres, Dániel Sándor Máthé, Domokos Budán, Ferenc Karádi, Éva Balikó, Anett Pajor, László Szomor, Árpád Schmidt, Erzsébet Alizadeh, Hussain Front Oncol Oncology PURPOSE: For the identification of high-risk patients in diffuse large B-cell lymphoma (DLBCL), we investigated the prognostic significance of in vivo radiomics derived from baseline [(18)F]FDG PET/CT and clinical parameters. METHODS: Pre-treatment [(18)F]FDG PET/CT scans of 85 patients diagnosed with DLBCL were assessed. The scans were carried out in two clinical centers. Two-year event-free survival (EFS) was defined. After delineation of lymphoma lesions, conventional PET parameters and in vivo radiomics were extracted. For 2-year EFS prognosis assessment, the Center 1 dataset was utilized as the training set and underwent automated machine learning analysis. The dataset of Center 2 was utilized as an independent test set to validate the established predictive model built by the dataset of Center 1. RESULTS: The automated machine learning analysis of the Center 1 dataset revealed that the most important features for building 2-year EFS are as follows: max diameter, neighbor gray tone difference matrix (NGTDM) busyness, total lesion glycolysis, total metabolic tumor volume, and NGTDM coarseness. The predictive model built on the Center 1 dataset yielded 79% sensitivity, 83% specificity, 69% positive predictive value, 89% negative predictive value, and 0.85 AUC by evaluating the Center 2 dataset. CONCLUSION: Based on our dual-center retrospective analysis, predicting 2-year EFS built on imaging features is feasible by utilizing high-performance automated machine learning. Frontiers Media S.A. 2022-06-08 /pmc/articles/PMC9216187/ /pubmed/35756658 http://dx.doi.org/10.3389/fonc.2022.820136 Text en Copyright © 2022 Ritter, Papp, Zámbó, Tóth, Dezső, Veres, Máthé, Budán, Karádi, Balikó, Pajor, Szomor, Schmidt and Alizadeh https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Ritter, Zsombor Papp, László Zámbó, Katalin Tóth, Zoltán Dezső, Dániel Veres, Dániel Sándor Máthé, Domokos Budán, Ferenc Karádi, Éva Balikó, Anett Pajor, László Szomor, Árpád Schmidt, Erzsébet Alizadeh, Hussain Two-Year Event-Free Survival Prediction in DLBCL Patients Based on In Vivo Radiomics and Clinical Parameters |
title | Two-Year Event-Free Survival Prediction in DLBCL Patients Based on In Vivo Radiomics and Clinical Parameters |
title_full | Two-Year Event-Free Survival Prediction in DLBCL Patients Based on In Vivo Radiomics and Clinical Parameters |
title_fullStr | Two-Year Event-Free Survival Prediction in DLBCL Patients Based on In Vivo Radiomics and Clinical Parameters |
title_full_unstemmed | Two-Year Event-Free Survival Prediction in DLBCL Patients Based on In Vivo Radiomics and Clinical Parameters |
title_short | Two-Year Event-Free Survival Prediction in DLBCL Patients Based on In Vivo Radiomics and Clinical Parameters |
title_sort | two-year event-free survival prediction in dlbcl patients based on in vivo radiomics and clinical parameters |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216187/ https://www.ncbi.nlm.nih.gov/pubmed/35756658 http://dx.doi.org/10.3389/fonc.2022.820136 |
work_keys_str_mv | AT ritterzsombor twoyeareventfreesurvivalpredictionindlbclpatientsbasedoninvivoradiomicsandclinicalparameters AT papplaszlo twoyeareventfreesurvivalpredictionindlbclpatientsbasedoninvivoradiomicsandclinicalparameters AT zambokatalin twoyeareventfreesurvivalpredictionindlbclpatientsbasedoninvivoradiomicsandclinicalparameters AT tothzoltan twoyeareventfreesurvivalpredictionindlbclpatientsbasedoninvivoradiomicsandclinicalparameters AT dezsodaniel twoyeareventfreesurvivalpredictionindlbclpatientsbasedoninvivoradiomicsandclinicalparameters AT veresdanielsandor twoyeareventfreesurvivalpredictionindlbclpatientsbasedoninvivoradiomicsandclinicalparameters AT mathedomokos twoyeareventfreesurvivalpredictionindlbclpatientsbasedoninvivoradiomicsandclinicalparameters AT budanferenc twoyeareventfreesurvivalpredictionindlbclpatientsbasedoninvivoradiomicsandclinicalparameters AT karadieva twoyeareventfreesurvivalpredictionindlbclpatientsbasedoninvivoradiomicsandclinicalparameters AT balikoanett twoyeareventfreesurvivalpredictionindlbclpatientsbasedoninvivoradiomicsandclinicalparameters AT pajorlaszlo twoyeareventfreesurvivalpredictionindlbclpatientsbasedoninvivoradiomicsandclinicalparameters AT szomorarpad twoyeareventfreesurvivalpredictionindlbclpatientsbasedoninvivoradiomicsandclinicalparameters AT schmidterzsebet twoyeareventfreesurvivalpredictionindlbclpatientsbasedoninvivoradiomicsandclinicalparameters AT alizadehhussain twoyeareventfreesurvivalpredictionindlbclpatientsbasedoninvivoradiomicsandclinicalparameters |